NCT04786028: Phase 2 - A Study of Isatuximab Added to Standard CyBorD Induction & Lenalidomide Maint
- Recruiting
- Jun 10, 2021
- 1 min read
Updated: May 24, 2022
NCT04786028: Phase 2 - A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM
A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM
A Phase 2 Multi-Center, Open Label Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in Newly Diagnosed, Transplant Eligible Multiple Myeloma
This is a phase II multi-center, open label, single arm study to evaluate the safety and efficacy of Isatuximab administered intravenously in combination with CyBorD induction treatment and Lenalidomide maintenance treatment in a 28-day long cycle in autologous stem cell transplant-eligible patients.
Sponsor
Canadian Myeloma Research Group
Location
Canada
ClinicalTrials.gov Identifier: NCT04786028
Official Title: A Phase 2 Multi-Center, Open Label Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in Newly Diagnosed, Transplant Eligible Multiple Myeloma
First Posted: March 8, 2021
Click here to see details on ClinicalTrials.gov
Locations
Canada, Alberta
Canada, Manitoba
Canada, Newfoundland and Labrador
Canada, Nova Scotia
Canada, Ontario
Canada, Saskatchewan